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Abstract
Background: In Italy many diabetics still lack adequate care in general practice. We assessed the effectiveness
of different strategies for the implementation of an evidence-based guideline for the management of non-
complicated type 2 diabetes among General Practitioners (GPs) of Lazio region.
Methods: Three-arm cluster-randomised controlled trial with GPs as units of randomisation (clusters). 252 GPs
were randomised either to an active strategy (training module with administration of the guideline), or to a passive
dissemination (administration of the guideline only), or to usual care (control). Data on prescriptions of tests and
drugs were collected by existing information systems, whereas patients' data came from GPs' databases. Process
outcomes were measured at the cluster level one year after the intervention. Primary outcomes concerned the
measurement of glycosilated haemoglobin and the commissioning of micro- and macrovascular complications
assessment tests. In order to assess the physicians' drug prescribing behaviour secondary outcomes were also
calculated.
Results: GPs identified 6395 uncomplicated type 2 patients with a high prevalence of cardiovascular risk factors.
Data on GPs baseline performance show low proportions of glycosilated haemoglobin assessments. Results of the
C-RCT analysis indicate that the active implementation strategy was ineffective relating to all primary outcomes
(respectively, OR 1.06 [95% IC: 0.76–1.46]; OR 1.07 [95% IC: 0.80–1.43]; OR 1.4 [95% IC:0.91–2.16]. Similarly,
passive dissemination of the guideline showed no effect.
Conclusion: In our region compliance of GPs with guidelines was not enhanced by a structured learning
programme. Implementation through organizational measures appears to be essential to induce behavioural
changes.
Trial registration: ISRCTN80116232.
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Background
In Italy diabetes mellitus (DM) is a major health problem
with a prevalence of 3–4% [1-3] and considerable
resources are committed to addressing treatment of
micro- and macrovascular complications [4]. In Italy,
patients with type 2 non-complicated DM are mainly
treated in general practice, whereas patients with type 1
DM and complicated patients usually receive specialist
care. Data from an unpublished survey, conducted in
2003 in a local health district of Lazio, showed that the
overall quality of DM care often fails to achieve estab-
lished standards, thus needing urgent intervention to raise
standards and protect those most vulnerable from the
consequences of DM. Strategies for changing general prac-
titioner's (GPs) behaviour by dissemination and imple-
mentation of guidelines and translating evidence into
practice are notoriously difficult areas [5-7]. A large sys-
tematic review by Grimshaw et al concluded that there is
an imperfect evidence base to support decisions on which
strategy is likely to be effective [8]. Further uncertainties
concern knowledge on service organisation and delivery
of diabetic care and the lack of comparative studies on the
effects of guideline implementation strategies in Italy.
We report on a cluster-randomised trial (C-RCT) to assess
the effects of two different strategies of introducing an evi-
dence-based guideline for the treatment of type 2 DM in
primary care. The C-RCT design (randomisation at the
level of professional practice or health care organization)
represents the optimal design when evaluating dissemina-
tion and implementation strategies [9]. As systematic
reviews can inform and contribute to the correct design of
randomised controlled trials, our protocol was based on
three Cochrane and one UK Health Technology Assess-
ment Programme systematic reviews of guideline dissem-
ination and implementation strategies [10-12].
Methods
Participants
Eligible study participants were GPs taking part in an elec-
tronically-linked disease surveillance network and receiv-
ing a specific fee for computer-made prescriptions; they
were about 50% of the whole population of Lazio GPs,
and on average younger than the non-using informative
instruments in their clinical practice. In order to minimize
the risk of contamination due to GPs working in associ-
ated forms, we used a software which assigned a zero
probability to be selected to members of the same prac-
tice, once one of them has already been extracted. Partici-
pants were recruited during the month of December 2003
and follow-up took place from January 2004 to December
2004.
Recruitment was performed by an invitation letter written
in a standardized format, giving information about the
study project. Every GP represented a cluster. The study
was carried out in the primary care setting of Italian
National Health Service in the Lazio region of Central
Italy, and was focused on the management of patients
with non-complicated type-2 DM, defined as diabetes dis-
ease in absence of even only one of the following condi-
tions: ocular complications (retinopathy, cataract, or
glaucoma); renal complications (nephropathy, chronic
renal failure); neurological complications (autonomic
neuropathy, peripheral neuropathy); diabetic foot
(deformity, Charcot foot, infection, ulcer, gangrene,
amputation); TIA/ictus; obstructive disease of lower
limbs.
In our design, GPs were "units of measure" (clusters) of
the process of diabetic care delivery, as they managed lab-
oratory and preventive care for most patients with type 2
DM. They were asked to identify their patients accordingly
to the above case definition and in observance with the
following exclusion criteria: age < 40 years; gestational
diabetes; diabetes in pregnancy.
Two different data sources were used. Patient descriptive
data (baseline information) were transmitted on-line by
GP participants who were given a login and a password to
access personal web pages. Data on prescriptions of drugs,
tests and outpatient appointment visits were extracted by
current information systems, which routinely assemble
data for reimbursement purposes, in particular the
Regional Drug Information System, which collects all pre-
scriptions of drugs reimbursed by the Italian NHS, and the
Ambulatory Care Information System, which gathers all
prescriptions of diagnostic tests and outpatient visits.
Data on the process of care for DM were collected during
the 12 months of follow-up after the intervention (year
2004) and main outcomes were constructed and assessed
from GPs' prescribing and commissioning behaviour.
Interventions
The intervention was structured learning and distribution
of the guideline to participant GPs (clusters).
Guideline choice
In order to choose an appropriate guideline we examined
the methodological issues on guideline evaluation and
implementation strategies and we conducted a systematic
search and evaluation of existing guidelines on diabetes
care [13-15]. We used the quality assessment criteria and
the quality assurance scores of the National Guideline
Program of the Italian Institute of Health [16] and we per-
formed a qualitative assessment of guidelines applicabil-
ity to our regional context. We chose a French guideline
[17], which we translated, updated and adapted for Italian
GPs.BMC Health Services Research 2007, 7:79 http://www.biomedcentral.com/1472-6963/7/79
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The intervention program
We structured the intervention program through a process
of identification of barriers to implementation of recom-
mendations and factors that may facilitate changing pro-
fessional behaviour, together with an estimation of the
resources available within the governance budget. We
developed the intervention to be preferably a single and
not a multi-faceted intervention, to be easy to carry out
and to be reproducible in the implementation of other
guidelines. The intervention program included either a
two-day training course with CME credits and dissemina-
tion of the guideline (arm 1, active implementation) or
dissemination of the guideline without the training
course but with a written request to implement the guide-
line (arm 2, passive dissemination). The control group
represented the usual care. The training course was organ-
ized as parallel sessions of teaching modules together with
interactive and group work sessions with discussion of the
content of the guideline. An entry questionnaire was given
to participants to obtain a picture of current care for dia-
betic patients.
Objectives
The primary objective of the study was to assess the effec-
tiveness of different strategies for the implementation of
an evidence-based guideline for the management of non-
complicated type 2 DM among GPs of the Lazio region.
Our null hypothesis was that a structured intervention
would be no more effective than a passive dissemination
of the guideline or of a no-intervention strategy. The sec-
ondary objective was to estimate the efficiency of resource
use associated with the intervention through a cost-effec-
tiveness analysis. Both the objectives were to be assessed
at cluster level.
Outcomes
Process of care variables were considered study outcomes,
all aimed at assessing physician-changing behaviour for
the 12 months following the intervention, by using data
from existing information systems. As Lazio GPs are not
trained to register clinical data for epidemiological pur-
poses, patient's health outcomes were not collected. Out-
comes were expressed as proportions of patients who were
prescribed requests for tests, for outpatient appointment
visits and drugs in the follow-up year. All outcomes were
evaluated at the patient level and aggregated to represent
clusters.
Primary outcomes
We evaluated GPs' adherence to guideline recommenda-
tions for diabetes management by the following assess-
ments: assessment of glycaemic control: we chose as
primary outcome the measurement of glycosilated hae-
moglobin, as the proportion of patients who were pre-
scribed 3 measurements of glycosilated haemoglobin
with at least two months' interval per year; assessment of
macrovascular complications aimed at early detection of
the risk of macrovascular complications of DM: we chose
as primary outcome the proportion of patients who were
prescribed all macrovascular complications assessment
tests (ECG and complete lipid profile, i.e. total choles-
terol, HDL cholesterol and tryglicerides simultaneously)
per year; assessment of microvascular complications
aimed at early detection of the risk of microvascular com-
plications of DM: we chose as primary outcome the pro-
portion of patients who were prescribed all microvascular
complications assessment tests (eye examination or fun-
dus and blood creatinine or creatinine clearance and
microalbuminuria) per year.
Secondary outcomes
To explore participant GPs' drug prescribing behaviour we
also calculated secondary outcomes, as indicators on
drugs prescribed for the management of the disease and of
correlated cardiovascular risk factors: pharmacological
management of DM, assessed by the proportion of over-
weight/obese diabetics who were prescribed methformin
in monotherapy as first-choice therapy and by the propor-
tion of elderly diabetics (>70 years) who were prescribed
long-life sulphonylureas (contraindicated in old age for
their long biological action which increases the risk of
hypoglycaemia); pharmacological management of cardio-
vascular risk factors, assessed by the proportion of diabet-
ics with at least 1 cardiovascular risk factor who were
prescribed anti-platelet drugs and by the proportion of
hypertensive diabetics who were prescribed first-choice
antihypertensive drugs in monotherapy; the proportion
of patients with dyslipidemia receiving lipid-lowering-
drugs.
For pharmacological indicators, patients were considered
as previously untreated if they had no medication pre-
scriptions recorded in the 12 months prior to the begin-
ning of the trial.
Sample size
The sample size calculation [18] took into account the
intra-cluster correlation coefficient, the number of events,
the expected effect, and the power of the study. On the
basis of the unpublished survey we assumed an intraclus-
ter correlation of ρ = 0.1 [19], an average of 15 diabetic
patients for each GP, and a worst-case control rate of 50%.
Under these assumptions we anticipated a power of 90%
to detect a difference of 10% in rates between one arm and
the other with α = 0.05 with 84 GP for each group. The
total sample size was 252 GPs.BMC Health Services Research 2007, 7:79 http://www.biomedcentral.com/1472-6963/7/79
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Randomisation
Sequence generation
Our randomisation sequences was computer-generated.
GPs who accepted to take part in the study, were assigned
by simple random allocation by the REXSCO [21] soft-
ware, which assigns to same-practice partners a nil proba-
bility of being randomised, thus minimising the chances
of participant contamination. Randomisation was per-
formed by a researcher not involved in the study and who
was blind to the identity of the practices.
Allocation concealment
Given the cluster design participant concealment was not
possible but data extraction and analysis was carried out
in blind fashion by one of us (DM).
Statistical methods
We carried out comparisons of primary outcomes
between the intervention and control arms at cluster (GP)
level as this was the unit of randomisation [22] and data
were analysed using a cluster specific method, Generalised
Estimating Equation (GEE) model [23,24].
Results
Participant flow
A flow-chart of the progress of clusters through the phases
of the trial is at Figure 1. We wrote to 2148 of the 4744
Lazio GPs who were known to be computer-literate
because they were in receipt of a computer allowance and
were users of regional surveillance software. Twenty five
percent (545) of eligible GPs agreed to take part (potential
participants). Of these we randomly assigned 84 "first
choices" and 36 "stand-ins" for each arm. As 43 GPs
declined to take further part after they had been notified
of the outcome of randomisation, we contacted a total of
295 potential participants (110 in arm 1, 91 in arm 2 and
94 in arm 3). Post-randomisation attrition was highest in
arm 1: 26 (60%) vs 6 (14%) vs 11 (26%) probably
because of the requirement to attend our course.
Baseline data
Tables 1 and 2 show the distribution of characteristics of
(respectively) participant GPs (clusters) and diabetic
patients cared by GPs (individuals). Baseline information
was available for 6290/6395 patients.
Flow diagram of the progress of clusters Figure 1
Flow diagram of the progress of clusters. Legend: *: Two-day training course + CME credits. ^ : Passive dissemination of the 
guideline. °: No intervention group, continuing current practice.
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Did not receive intervention (No of clusters: 26) 
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Table 2: Baseline information on patients for whom information was available (6290/6395) cared by GP participants
Item Active implementation No (%) Passive dissemination No (%) Usual care No (%)
Gender F 971(50) 991(47) 1060(47)
M 981(50) 1115(53) 1172(53)
total 1952 2106 2232
Age (years) <50 139 (7) 119 (6) 128 (6)
50–70 1089 (56) 1155 (55) 1279 (57)
>70 724 (37) 832 (39) 825 (37)
Patient managed by GP only 801 (41) 936 (44) 1056 (47)
GP with specialist 1130 (58) 1133 (54) 1115 (50)
Integrated care 21 (1) 37 (2) 61 (3)
Diabetes duration (years) <5 691 (35) 673 (32) 781 (35)
5–10 718 (37) 778 (37) 803 (36)
11–20 364 (19) 479 (23) 456 (20)
>20 80 (4) 126 (6) 157 (7)
Not known 99 (5) 50 (2) 35 (2)
Glycaemic control Optimal 457 (23) 571 (27) 495 (22)
Acceptable 1005 (52) 1111 (53) 1140 (51)
Inadequate 331 (17) 362 (17) 374 (17)
Not known 159 (8) 62 (3) 223 (10)
Therapy Diet only 319 (16) 254 (12) 358 (16)
Pharmacological 1633 (84) 1852(88) 1874(84)
Hypertension Yes 1183 (61) 1334 (63) 1334 (60)
No 748 (38) 741 (35) 864 (39)
Not known 21 (1) 31 (2) 34 (1)
Hypercolesterolemia Yes 802 (41) 952 (45) 1037 (47)
No 1066 (55) 1085 (52) 1099 (49)
Not known 84 (4) 69 (3) 96 (4)
Smoking Yes 336 (17) 416 (20) 400 (18)
No 1494 (77) 1597 (76) 1672 (75)
Not known 122 (6) 93 (4) 160 (7)
BMI Normal (<25) 351 (18) 374 (18) 365 (16)
Overweight (25–29) 628 (32) 726 (35) 771 (35)
Obese (>29) 307 (16) 366 (17) 370 (17)
Not known 666(34) 640 (30) 726 (33)
Table 1: Baseline information on GP participants (clusters)
Item Active implementation Passive dissemination Usual care Total
No of participant GPs 84 85 83 252
Mean age (SD) (in years) 48.7* (4.3) 50.6 (4.9) 50.7 (4.8) 50.0 (4.7)
No (%) by gender M 69 (82) 72 (85) 72 (87) 213 (85)
F 15 (18) 13 (15) 11 (13) 39 (15)
Mean (SD) seniority (in years) 14.6 (6.3) 16.3 (7.0) 16.8 (6.8) 15.9 (6.8)
No (%) of GPs with <500 patients 9 (11) 4 (5) 9 (11) 22 (9)
No (%) of GPs with 500–1000 patients 16 (19) 18 (21) 11 (13) 45 (18)
No (%) of GPs with >1000 patients 59 (70) 63 (74) 63 (76) 185 (73)
No of diabetic patients 1973 2190 2232 6395
Mean (SD) diabetic patients per GP 23.5 (13.0) 25.8 (14.7) 26.9 (17.5) 25.4 (15.1)
No (%) of singleton GPs 21 (25) 18 (21) 13 (16) 52 (21)
No (%) in group practices 63 (75) 67 (79) 70 (84) 200 (79)
No (%) of GPs practicing in Rome 47 (56) 49 (58) 41 (49) 137 (54)
No (%) of GPs practicing in suburbs of Rome 14 (17) 13 (15) 15 (18) 42 (17)
No (%) of GPs practicing elsewhere in Lazio 23 (27) 23 (27) 27 (33) 73 (29)
*p < 0.017 = pBonferroniBMC Health Services Research 2007, 7:79 http://www.biomedcentral.com/1472-6963/7/79
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Numbers analysed
We carried out two analyses, one by including all 252 par-
ticipant GPs (84 in arm 1, 85 in arm 2 and 83 in arm 3)
who had identified their DM type 2 patients and the sec-
ond, per protocol analysis (PPA), on the 235 participants
who had identified their patients, provided their baselines
characteristics and taken part in the full course (arm 1
only) (71 in arm 1, 81 in arm 2 and 83 in arm 3).
Outcomes and estimation
Table 3 shows pre-intervention (year 2003) and post-
intervention (year 2004) values of primary outcomes
together with their individual components and change
over time for each of the 3 arms.
C-RCT results obtained processing data from all 252 clus-
ters are shown in Table 4.
Active implementation vs usual care
Analyses of data measuring the impact of the active strat-
egy shows that there was no effect either on the metabolic
control indicator (OR 1,06 [0,76–1,46]), or on macrovas-
cular complications assessment tests (OR 1,07 [0,80–
Table 4: Results of C-RCT analysis (year 2004) performed on all 252 GPs recruited
Principal indicator Arm Value ICC OR 95% CI
Metabolic control Active implementation 11,9 % 0,069 1,06 (0,76 – 1,46)
Passive dissemination 10,1 % 0,93 (0,67 – 1,30)
Usual care 10,3 % 1
Macrovascular complications Active implementation 14,0 % 0,054 1,07 (0,80 – 1,43)
Passive dissemination 11,7 % 0,93 (0,70 – 1,24)
Usual care 12,4 % 1
Microvascular complications Active implementation 6,9 % 0,046 1,4 (0,91 – 2,16)
Passive dissemination 4,9 % 1,11 (0,73 – 1,69)
Usual care 4,7 % 1
ICC = intracluster correlation coefficient; OR = odds ratio; 95% CI = confidence interval
Table 3: Pre-intervention (year 2003) and post-intervention (year 2004) values of primary outcomes, their individual components (in 
brackets) and change over time for each of the 3 arms
Primary outcomes 
(Individual components)
Arm Pre-intervention value 
%
Post-intervention value 
%
Δ%
Metabolic control Active implementation 11,0 (218/1973) 11,9 (235/1973) 7,8
Passive dissemination 7,7 (169/2190) 10,1 (222/2190) 31,4
Usual care 8,8 (196/2232) 10,3 (230/2232) 17,3
Macrovascular 
complications
Active implementation 12,7 (250/1973) 14,0 (277/1973) 10,8
Passive dissemination 10,7 (235/2190) 11,7 (257/2190) 9,4
Usual care 10,9 (244/2232) 12,4 (277/2232) 13,5
(ECG) Active implementation 26,1 (515/1973) 26,0 (513/1973) -0,4
Passive dissemination 25,9 (568/2190) 25,0 (547/2190) -3,7
Usual care 24,9 (555/2232) 24,2 (541/2232) -2,5
(Lipid profile) Active implementation 30,8 (608/1973) 35,7 (705/1973) 16,0
Passive dissemination 25,7 (563/2190) 28,5 (624/2190) 10,8
Usual care 25,0 (559/2232) 30,3 (677/2232) 21,1
Microvascular 
complications
Active implementation 5,3 (104/1973) 6,9 (136/1973) 30,8
Passive dissemination 4,5 (98/2190) 4,9 (108/2190) 10,2
Usual care 5,0 (112/2232) 4,7 (105/2232) -6,3
(Retinal screening) Active implementation 25,0 (494/1973) 26,6 (525/1973) 6,3
Passive dissemination 24,2 (530/2190) 23,9 (523/2190) -1,3
Usual care 22,9 (512/2232) 22,7 (507/2232) -1,0
(Microalbuminuria) Active implementation 10,5 (208/1973) 13,7 (271/1973) 30,3
Passive dissemination 8,7 (191/2190) 10,5 (229/2190) 19,9
Usual care 9,8 (219/2232) 11,9 (265/2232) 21,0
(Creatinine serum level) Active implementation 54,6 (1078/1973) 54,2 (1070/1973) -0,7
Passive dissemination 48,7 (1067/2190) 51,6 (1129/2190) 5,8
Usual care 47,1 (1052/2232) 50,4 (1124/2232) 6,8BMC Health Services Research 2007, 7:79 http://www.biomedcentral.com/1472-6963/7/79
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1,43]) or on microvascular complications assessment tests
(OR 1,4 [0,91–2,16]).
Passive dissemination vs usual care
Analyses of data measuring the effect of passive dissemi-
nation of the guideline shows similar results for all the
three primary outcomes, respectively OR 0,93 [0,67–1,30]
for the metabolic assessment, OR 0,93 [0,70–1,24] for the
macrovascular complications assessment test and OR 1,11
[0,73–1,69] for the microvascular complications assess-
ment test.
Per protocol analyses gives similar results (data not shown).
On the basis of analyses of per protocol data and of data
relating to all 252 clusters we cannot reject our null hypo-
thesis, as our findings show an absence of correlation
between active or passive educational training of GPs and
physicians attitude at following the indications of the
guideline. As results showed the non-effectiveness of the
intervention strategy, we did not perform any economic
evaluation or carry out analysis on participant sub-clus-
ters.
Discussion and Conclusion
Our trial did not show significative differences between
arms in the effectiveness of two different strategies to
implement a good quality guideline for caring for people
with type 2 uncomplicated diabetes. The dissemination of
our guideline and a specifically targeted educational pro-
gram seemed to unable to persuade GPs to change their
current clinical practice. Although disappointing to us,
these findings represent the first experimental evidence of
the problems of putting evidence into practice available in
Italy. They suggest that at both regional and national level
there is an urgent requirement to attempt complex and
articulated paths in an effort to increase quality of care.
There is a growing body of evidence about the importance
of an existing definite organizational framework as the
basis for any changing behaviour by health care providers
[25,26] and a recent systematic review highlights a sub-
stantial improvement in patient glycaemic control using
case management [27]. Disease management models
have been recently introduced in some regions, but
although some pilot studies have shown promise [28],
substantial differences between regional contexts may
make these results not generally applicable. In Lazio many
community services are performed by hospital outpatient
departments with scarce integration between hospital and
community and between primary and secondary care.
This lack of integration is reflected in patchy information
exchange between operators. An important issue is the
generalisability (or external validity) of the trial's findings
at the cluster (GP) level. Available systematic reviews [7-9]
reported possible non-specific effects on the control arms
of C-RCTs which could hinder generalisability of results.
In Lazio there are very scarce data on knowledge and per-
ception of guidelines and commonly GPs have difficulty
in being involved in institutional programs for improving
the quality of care. For a number of reasons [29,30]. Inter-
nal barriers include time constraints, possibly inadequate
reimbursement and disagreement with innovative pro-
grams. External barriers include individual patient needs,
limited systems to support chronic disease management
and poor patient adherence to treatment. In addition a
large part of GPs may not be accustomed to web-based
data loading and may not be accustomed to taking part in
trials. It is possible that the performance of the control
group (current practice arm) could have been different
from other current practice with unconscious improve-
ment from the beginning of the trial when control partic-
ipants were asked to define and transmit a set of data
relating to their DM patients. This may have had an
impact on the applicability of our results. Conversely
some contamination with participants belonging to dif-
ferent arms cannot be discounted, although we have no
proof of its occurrence. The conclusions of our study are
not very different from those reported by a survey con-
ducted in 2004 by the Italian Institute of Health on a pop-
ulation of diabetics sampled in all Italian regions, which
reported scarce adherence to clinical guidelines either by
GPs or by specialists and large opportunities for improve-
ment of care [31]. Evidence from systematic reviews is at
present unable to point to the most effective way of
changing doctors' behaviour because of poor methodo-
logical quality of the majority of the included studies
(major recurring problems were unit of analysis errors,
baseline imbalance and within-group rather than between
groups comparisons). In addition most studies used proc-
ess measures for their primary end-point (like we did) and
real improvements in health remained an issue of debate.
In conclusion the effectiveness of implementation strate-
gies is strongly correlated to the local context and could
largely vary under different circumstances. Efforts should
be directed to increase the body of evidence with more
and better quality comparative studies. At the same time,
policy makers have the responsibility to administrate the
limited resources for clinical governance on the basis of a
thorough knowledge of settings and problems.
The following are apparent limits of trial: uncertain repre-
sentativeness of enrolled GPs compared to the remaining
GPs which could affect external validity of our results; bet-
ter performance of enrolled GPs; non-attendance for
teaching sessions rate (13 out of 84, 15%).
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